MedTechIndexBETA
The MedTechIndex Briefing

Keep up with MedTechIndex.

A weekly note from Blair, new companies added to the directory, and meaningful updates to existing profiles.

Confirm your email to join. Email privacy

Companies / eKare
Medical device company profile

eKare

Digital wound imaging, measurement, documentation and analytics for clinical care and research.

Medical Device ManufacturerDiagnostics & ImagingGeneral Medical & Patient CareDiagnostic ImagingWound CareCommercial-stage
Headquarters🇺🇸Fairfax, Virginia, United States
Founded2014
Commercial statusCommercially availableSelected products commercially offered; availability and indications vary by product and market.
EmployeesNot confirmed
Estimated revenueNot confirmed
Official websiteekare.ai ↗

Company overview

eKare provides digital wound imaging and measurement technology through its inSight platform. Founded in 2014 as a spin-off from Children’s National Medical Center, the company combines mobile imaging, wound documentation, workflow tools and analytics for care providers and clinical research organizations.

The company lists its U.S. address in Fairfax, Virginia, alongside a European business in the Netherlands. Patrick Cheng is CEO and co-founder, with Kyle Wu serving as Chief Medical Officer. The product is offered commercially for clinical practice and research workflows.

Company support materials identify inSight as FDA registered under product code FXN, while FDA classification describes the surgical-camera category as 510(k) exempt. This is not a verified 510(k) clearance of every AI feature, diagnostic claim or later software configuration. Product-version and intended-use mapping remain important research boundaries.

[3][4][5][7]

Leadership

3 people
Patrick ChengChief Executive Officer & Co-Founder [5]
Kyle L. WuChief Medical Officer [5]
Dan YorkChief Commercial Officer [5]

Products & regulatory status How does MedTechIndex get this information?

Summary

Manufacturer support identifies inSight with FDA product code FXN. The reviewed classification is 510(k) exempt; later software configurations and AI claims require separate mapping. Exemption is not FDA approval; intended use, labeling and applicable exemption limitations still govern marketing. [1][2][3][4][8]

No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [10][11]

Regulatory snapshot How to read this snapshot

U.S. FDA
0
510(k) clearances
0
De Novo grants
0
PMA approvals
0
Recall events

Latest recorded source review: 2026-10-20.

Commercial portfolio snapshot

Documented commercial product families.

Digital wound imaging and measurement

inSight wound measurement platform ↗

Mobile wound imaging, measurement and documentation platform with clinical and research workflows. [7][1][2]

Exemption documented

Commercially offered; exact model and country availability should be confirmed with the manufacturer.

Commercial development

Commercial development spans clinical wound-care workflows, research imaging and mobile capture. No blanket FDA authorization is inferred for all AI analytics or newer software functions. [4][3]

Activity & Milestones

1 events
2014 · Corporate

Company founded

Company history describes a 2014 spin-off from Children’s National Medical Center. [7]

13 Cited Sources

Accessed 10/20/2026

Company research

Compare companies

Privacy choices

Your saved-company and comparison preferences are stored separately. Changing analytics preferences does not clear them.

About cookies and privacy